Monarch Partners Asset Management LLC Has $386,000 Holdings in Recro Pharma Inc (REPH)

Share on StockTwits

Monarch Partners Asset Management LLC raised its position in shares of Recro Pharma Inc (NASDAQ:REPH) by 18.0% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 65,917 shares of the specialty pharmaceutical company’s stock after buying an additional 10,060 shares during the quarter. Monarch Partners Asset Management LLC’s holdings in Recro Pharma were worth $386,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in REPH. Meeder Asset Management Inc. lifted its position in shares of Recro Pharma by 191.1% during the first quarter. Meeder Asset Management Inc. now owns 5,086 shares of the specialty pharmaceutical company’s stock valued at $30,000 after buying an additional 3,339 shares during the last quarter. Truvestments Capital LLC purchased a new position in shares of Recro Pharma in the 1st quarter valued at approximately $38,000. Virtu Financial LLC raised its position in shares of Recro Pharma by 27.7% in the 1st quarter. Virtu Financial LLC now owns 12,875 shares of the specialty pharmaceutical company’s stock valued at $75,000 after purchasing an additional 2,795 shares during the last quarter. Rhumbline Advisers raised its position in shares of Recro Pharma by 47.8% in the 4th quarter. Rhumbline Advisers now owns 23,753 shares of the specialty pharmaceutical company’s stock valued at $169,000 after purchasing an additional 7,679 shares during the last quarter. Finally, Bank of America Corp DE raised its position in shares of Recro Pharma by 210.4% in the 4th quarter. Bank of America Corp DE now owns 27,182 shares of the specialty pharmaceutical company’s stock valued at $193,000 after purchasing an additional 18,424 shares during the last quarter. 57.90% of the stock is owned by institutional investors and hedge funds.

In other Recro Pharma news, Director Arnaud Ajdler purchased 40,000 shares of the business’s stock in a transaction that occurred on Friday, May 17th. The shares were bought at an average price of $9.00 per share, for a total transaction of $360,000.00. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Geraldine Henwood sold 144,806 shares of the stock in a transaction that occurred on Monday, May 13th. The stock was sold at an average price of $8.89, for a total transaction of $1,287,325.34. Following the completion of the transaction, the chief executive officer now owns 342,947 shares in the company, valued at approximately $3,048,798.83. The disclosure for this sale can be found here. 20.10% of the stock is currently owned by corporate insiders.

Shares of Recro Pharma stock opened at $9.39 on Friday. The company has a market capitalization of $208.28 million, a P/E ratio of -3.77 and a beta of -0.13. The company has a quick ratio of 3.18, a current ratio of 3.56 and a debt-to-equity ratio of 4.04. Recro Pharma Inc has a 52 week low of $4.78 and a 52 week high of $10.32.

Recro Pharma (NASDAQ:REPH) last announced its quarterly earnings data on Friday, May 10th. The specialty pharmaceutical company reported ($0.10) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.79) by $0.69. Recro Pharma had a negative net margin of 83.56% and a negative return on equity of 472.52%. The firm had revenue of $25.07 million during the quarter, compared to analyst estimates of $20.51 million. Analysts expect that Recro Pharma Inc will post -0.54 EPS for the current fiscal year.

Several equities analysts recently commented on the stock. ValuEngine lowered shares of Recro Pharma from a “buy” rating to a “hold” rating in a research report on Monday, March 25th. Zacks Investment Research raised shares of Recro Pharma from a “hold” rating to a “buy” rating and set a $9.25 price objective for the company in a research report on Wednesday, April 24th. Roth Capital reaffirmed a “neutral” rating and issued a $7.50 price objective (down from $15.00) on shares of Recro Pharma in a research report on Monday, March 25th. Oppenheimer set a $18.00 price objective on shares of Recro Pharma and gave the company a “buy” rating in a research report on Wednesday, February 20th. Finally, Janney Montgomery Scott reaffirmed a “buy” rating and issued a $13.00 price objective on shares of Recro Pharma in a research report on Thursday, January 31st. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $10.95.

WARNING: “Monarch Partners Asset Management LLC Has $386,000 Holdings in Recro Pharma Inc (REPH)” was first reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this article on another website, it was copied illegally and reposted in violation of international copyright legislation. The original version of this article can be read at https://www.tickerreport.com/banking-finance/4353401/monarch-partners-asset-management-llc-has-386000-holdings-in-recro-pharma-inc-reph.html.

About Recro Pharma

Recro Pharma, Inc, a specialty pharmaceutical company, develops and commercializes products for hospital and related acute care settings. The company operates in two segments, Acute Care, and Contract Development and Manufacturing. Its lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.

Recommended Story: How can you know how many shares are floating?

Want to see what other hedge funds are holding REPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Recro Pharma Inc (NASDAQ:REPH).

Institutional Ownership by Quarter for Recro Pharma (NASDAQ:REPH)

Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Barry Zwarenstein Sells 7,663 Shares of Five9 Inc  Stock
Barry Zwarenstein Sells 7,663 Shares of Five9 Inc Stock
Venture Fund Vii L.P. Arch Sells 63,000 Shares of Syros Pharmaceuticals Inc  Stock
Venture Fund Vii L.P. Arch Sells 63,000 Shares of Syros Pharmaceuticals Inc Stock
Insider Selling: Neogen Co.  Director Sells 5,000 Shares of Stock
Insider Selling: Neogen Co. Director Sells 5,000 Shares of Stock
Neogen Co.  Director Sells $314,650.00 in Stock
Neogen Co. Director Sells $314,650.00 in Stock
Insider Selling: Airgain Inc  CEO Sells 22,464 Shares of Stock
Insider Selling: Airgain Inc CEO Sells 22,464 Shares of Stock
Insider Selling: Bottomline Technologies  Insider Sells 9,925 Shares of Stock
Insider Selling: Bottomline Technologies Insider Sells 9,925 Shares of Stock


© 2006-2019 Ticker Report